Latest Announcements

Time Technoplast Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with a 32% and 29% increase in revenue, respectively. The company achieved a 18% and 17% growth in EBITDA, and a 27% and 25% growth in PAT for the quarter and half year, respectively.

Veegaland Developers Limited has announced its unaudited financial results for the quarter ended September 30, 2026, with revenue up by 29% YoY to ₹ 106.3 Cr, EBITDA up by 78% YoY to ₹ 22.8 Cr, and PAT up by 92% YoY to ₹ 16.0 Cr.

Rashi Peripherals Ltd announced its unaudited financial results for Q2 & H1 FY 2026-27, recording its highest-ever profit in both periods, driven by strategic expansion into high-growth technology segments. The company's revenue from operations stood at INR 61,851 million in Q2 and INR 112,870 million in H1, with EBITDA margins of 3.56% and 3.33% respectively. Net profit for Q2 stood at INR 1,307 million and INR 2,353 million in H1, with YoY growth of 120.8% and 94.6% respectively.

Kingfa Science & Technology (India) Limited has announced its performance update for Q2-FY 2026-27, showing a 52.18% YoY increase in net revenue from operations to Rs. 141,165.40 lakhs. Domestic sales increased by 53.4% and export sales by 37.2% YoY. The company's net profit for the period before tax stood at Rs. 6,348.55 lakhs, and earnings per share were Rs. 34.71.

VTM Limited has reported a 9.2% YoY increase in net sales and a 38.9% YoY increase in EBITDA for the quarter ended September 30, 2026. The company's gross margin improved by 25.3% YoY, and its PAT increased by 26.6% YoY. The management's opinion highlights key takeaways from the quarter, including an increase in other costs, a rise in fixed charges, and a lag in total comprehensive income.

Healthcare Global Enterprises Limited has announced its unaudited financial results for the quarter and six months ended September 30, 2026, with revenue up by 16% YoY and Adjusted EBITDA up by 17% YoY.

Kingfa Science & Technology (India) Ltd. has released its Q2 FY 2026-27 performance update, showing a 52.18% YoY increase in total revenue from operations to Rs. 141,165.40 lakhs, with domestic sales increasing by 53.4% and export sales by 37.2% YoY. Net revenue from operations stood at Rs. 141,165.40 lakhs, compared to Rs. 92,762.34 lakhs in the corresponding period of the previous financial year.

Bella Casa Fashion & Retail Limited has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with a 20% YoY increase in revenue to ₹259 crores, and a profit after tax of ₹6.5 crores.

VA Tech Wabag Ltd announced its unaudited financial results for the quarter and half year ended September 30, 2026, with a strong order book of ~INR 202 Bn and robust revenue visibility. The company secured multiple orders from RIL, including a 'Mega' order for desalination and remineralisation plants, and a repeat 'Medium' order for an ETP at DAGEGC, Jamnagar. The results showed a 20.7% growth in revenue and a 19.9% growth in EBITDA for H1 FY27 compared to H1 FY26.

Welspun Enterprises Ltd informed the Exchange about Investor Presentation for the quarter and half year ended September 30, 2026, with a 32% YoY revenue growth and 122% YoY EBITDA growth.

HealthCare Global Enterprises Ltd has announced its unaudited financial results for the quarter and six months ended September 30, 2026, with revenue up by 16% YoY and Adjusted EBITDA up by 17% YoY.

Ugro Capital Limited has informed the Exchange about the Shareholder Letter - Quarter ended 30 September 2026, highlighting record disbursements, a shift in portfolio, and the merger of Profectus.

VA Tech Wabag Limited has informed the Exchange about Investor Presentation for Q2 & H1 FY 2027, highlighting robust top-line growth, strong profit momentum, and a defining milestone of crossing Rs. 20,000 crores in order book for the first time ever.

Shree Pushkar Chemicals & Fertilisers Limited has informed the Exchange about Transcript of Analyst/Investor Conference Call held on Tuesday, 3rd November, 2026. The company's Q2 H1 FY27 Results Conference Call was attended by Mr. Punit Makharia, Chairman and Managing Director, and Mr. Deepak Beriwala, Chief Financial Officer. The company reported a strong performance during the second quarter of FY27 with significant growth in revenue and profitability across the company's chemical and fertilizer business.

Time Technoplast Limited has informed the Exchange about Investor Presentation, enclosing a copy of the 'Earnings Presentation' for the Quarter and Half Year ended September 30, 2026, with highlights of highest-ever quarterly performance in revenue, EBITDA, and PAT.

Pearl Global Industries Limited has informed the Exchange regarding Outcome of Board Meeting held on November 05, 2026. The Board of Directors have approved the unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026, along with Limited Review Report issued by the Statutory Auditors of the Company. The Board has also declared the 1st Interim Dividend of Rs. 5/- per equity share i.e. 100% on face value of Rs. 5/- each for the Financial Year 2026-27.

Jyoti Resins & Adhesives Limited has submitted its Q2 and FY27 Investor Presentation on un-audited financial results for the quarter and half year ended September 30, 2026, with a 31.3% YoY revenue growth and 23% EBITDA margin.

Symbiotec Pharmalab Limited has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with a 43% revenue growth and 169% PAT growth on a Y-o-Y basis. The company has also signed a licensing agreement for distribution of two DCV products in the US and has completed milestones invoiced and part revenue recognized in Q2 FY27.

GHCL Textiles Limited announced its unaudited financial results for Q2/H1 FY27, with PAT growing by 249% YoY to Rs. 56 crores and revenue growing by 31% YoY to Rs. 446 crores. The company's share of revenue from fabric has increased to 16.4% compared to 11.4% in Q2 FY26. The Board has approved the unaudited financial results for the quarter and half year ended on September 30, 2026.

Symbiotec Pharmalab Limited has informed the Exchange about Investor Presentation for Q2 & H1FY27, highlighting strong business momentum, steady revenue growth, and emerging growth engines.